Focus Partners Wealth
MGX icon

Focus Partners Wealth’s Metagenomi Therapeutics MGX Stock Holding History

Focus Partners Wealth’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,381
Closed -$98.8K – 2045
2024
Q4 		$98.8K Buy
+27,381
New +$66.1K ﹤0.01% 1796

Other funds holding MGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Focus Partners Wealth's MGX Position: Q1 2025 in Review

Focus Partners Wealth sold out of Metagenomi Therapeutics (MGX) in Q1 2025, closing a stake of 27,381 shares — an estimated $98.8K sold.

Focus Partners Wealth first reported a position in MGX in Q4 2024 and held it in 1 quarter. The position peaked at $98.8K in Q4 2024. 79 funds tracked by Wall St. Rank hold MGX as of Q1 2025.

  • Focus Partners Wealth reported no remaining Metagenomi Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Focus Partners Wealth sold 27,381 Metagenomi Therapeutics shares in Q1 2025, an estimated $98.8K.
  • Focus Partners Wealth first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 1 quarter.
  • Focus Partners Wealth's Metagenomi Therapeutics position peaked at $98.8K in Q4 2024.
  • 79 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2025.

Based on Focus Partners Wealth's 13F filing for Q1 2025, filed 15 May 2025.